The peptidyl-prolyl isomerase, Pin1, is exploited in cancer to activate oncogenes and inactivate
tumor suppressors. However, despite considerable efforts, Pin1 has remained an elusive …

Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin1) is commonly overexpressed in
human cancers, including pancreatic ductal adenocarcinoma (PDAC). While Pin1 is …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to
current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and …

The G1/S cell cycle checkpoint is frequently dysregulated in cancer, leaving cancer cells reliant
on a functional G2/M checkpoint to prevent excessive DNA damage. Wee1 regulates the …

While there are hundreds of predicted E3 ligases, characterizing their applications for
targeted protein degradation has proved challenging. Here, we report a chemical biology …

Propofol, an intravenous anesthetic, is a positive modulator of the GABA A receptor, but the
mechanistic details, including the relevant binding sites and alternative targets, remain …

Propofol, an intravenous anesthetic, is a positive modulator of the GABAA receptor, but the
mechanistic details, including the relevant binding sites and alternative targets, remain …

The peptidyl-prolyl cis-trans isomerase, Pin1, acts as a unified signaling hub that is exploited
in cancer to activate oncogenes and inactivate tumor suppressors, in particular through up-…

Targeted protein degradation is a rapidly developing therapeutic modality that promises lower
dosing and enhanced selectivity as compared to traditional occupancy-driven inhibitors, …

Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) combination safely cures fatal acute
promyelocytic leukemia, but their mechanisms of action and efficacy are not fully understood…